Abstract
Drug development targeting CD137 has been historically fraught because of concerns over safety and efficacy. A deeper understanding of CD137 function and insights into why earlier CD137 agonists failed have set the stage for a new generation of promising CD137 therapeutics. See related article by de Bono et al., p. 3388.